Roth Capital Upgrades Tonix Pharma (TNXP) to Buy

April 18, 2019 8:08 AM EDT
Get Alerts TNXP Hot Sheet
Price: $0.55 --0%

Rating Summary:
    4 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 8
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Roth Capital analyst Scott Henry upgraded Tonix Pharma (NASDAQ: TNXP) from Neutral to Buy with a price target of $4.00.

The analyst comments "The key takeaways, in our opinion, include 1) TNXP is attempting its third shot at the PTSD indication with the "RECOVERY" trial, 2) enrollment adjustments give the trial a reasonable shot at success, 3) the cash runway could get the company to the key PTSD data readout in 1H20, and 4) the stock looks interesting using only a ~20% chance at approval."

For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.

Shares of Tonix Pharma closed at $2.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Related Entities

Roth Capital